Eli Lilly’s eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.
Latest Ratings for LLY
DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022MizuhoMaintainsBuy Jan 2022Morgan StanleyMaintainsOverweight